UK Markets closed

Acceleron Pharma Inc. (XLRN)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
179.680.00 (0.00%)
At close: 04:00PM EST
Full screen
Trade prices are not sourced from all markets
Previous close179.68
Open179.71
Bid179.51 x 800
Ask179.80 x 900
Day's range179.66 - 179.77
52-week range111.75 - 189.99
Volume1,021,458
Avg. volume1,335,584
Market cap10.906B
Beta (5Y monthly)0.35
PE ratio (TTM)N/A
EPS (TTM)-3.05
Earnings date23 Feb 2022 - 28 Feb 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est154.50
  • Motley Fool

    Is Merck's Planned Acquisition of Acceleron in Trouble?

    In September, Merck (NYSE: MRK) announced plans to acquire Acceleron Pharma (NASDAQ: XLRN) for $11.5 billion. In this Motley Fool Live video recorded on Nov. 3, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss why Merck's move doesn't mean that the acquisition of Acceleron is in trouble.

  • Business Wire

    Avoro Capital Releases Presentation Detailing Why Acceleron Shareholders Should Not Tender Into Merck’s Inadequate Offer

    NEW YORK, November 09, 2021--Avoro Capital Advisors ("Avoro"), a long-term and collaborative investor in life sciences and biotechnology companies, together with certain of its affiliates and managed funds ("Avoro," "we" or "us") beneficially owns approximately 7% of Acceleron Pharma Inc. (Nasdaq: XLRN) ("Acceleron", "XLRN" or the "Company"), making Avoro one of the Company's most significant shareholders. Avoro today released a detailed presentation outlining why shareholders should not tender

  • Zacks

    Acceleron Pharma (XLRN) Reports Q3 Loss, Lags Revenue Estimates

    Acceleron (XLRN) delivered earnings and revenue surprises of 1.04% and -6.62%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?